December 6, 2021 -- Aslan Pharmaceuticals has appointed Iqvia as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion, and engagement of patients for trials related to the clinical development of Aslan004 and Aslan003.
Aslan004 is a potential antibody targeting the IL-13 receptor. It is currently being evaluated for use in atopic dermatitis. Aslan003 is a potent oral inhibitor of dihydroorotate dehydrogenase, which is being developed for the treatment of autoimmune disease.
Iqvia will provide patient recruitment, clinical monitoring, medical writing, and biostatistics for Aslan's upcoming 300-patient phase IIb trial of Aslan004 in adults with moderate to severe atopic dermatitis. Iqvia will work closely with Aslan to oversee clinical operations and recruit patients in the United States, Canada, Europe, and Asia.
Iqvia is also positioned to collaborate with Aslan's clinical operations team on future development plans for Aslan003 in inflammatory bowel disease, with clinical trials starting early next year. Enrollment in the Aslan004 phase IIb trial is expected in the fourth quarter of 2021.
Copyright © 2021 scienceboard.net